These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 1348429)

  • 21. Regional distribution of pre- and postsynaptic glutamatergic function in Alzheimer's disease.
    Cowburn R; Hardy J; Roberts P; Briggs R
    Brain Res; 1988 Jun; 452(1-2):403-7. PubMed ID: 2900052
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dysfunctional synapse in Alzheimer's disease - A focus on NMDA receptors.
    Mota SI; Ferreira IL; Rego AC
    Neuropharmacology; 2014 Jan; 76 Pt A():16-26. PubMed ID: 23973316
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Glutamate and Alzheimer's disease].
    Gazulla J; Cavero-Nagore M
    Rev Neurol; 2006 Apr 1-15; 42(7):427-32. PubMed ID: 16602060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease.
    Geerts H; Grossberg GT
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):8S-16S. PubMed ID: 16809810
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glutamate receptor antagonism: neurotoxicity, anti-akinetic effects, and psychosis.
    Riederer P; Lange KW; Kornhuber J; Jellinger K
    J Neural Transm Suppl; 1991; 34():203-10. PubMed ID: 1687783
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential regulation of glutamate receptors in Alzheimer's disease.
    Lee HG; Zhu X; Ghanbari HA; Ogawa O; Raina AK; O'Neill MJ; Perry G; Smith MA
    Neurosignals; 2002; 11(5):282-92. PubMed ID: 12566929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Memantine: from the original brand to generics].
    Titova NV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10):136-143. PubMed ID: 29171502
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Presynaptic glutamate receptors regulate noradrenaline release from isolated nerve terminals.
    Wang JK; Andrews H; Thukral V
    J Neurochem; 1992 Jan; 58(1):204-11. PubMed ID: 1345765
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Excitatory amino acids and neuropsychiatric disorders.
    Olney JW
    Biol Psychiatry; 1989 Sep; 26(5):505-25. PubMed ID: 2571362
    [No Abstract]   [Full Text] [Related]  

  • 30. N-methyl-D-aspartic acid (NMDA) and non-NMDA receptors regulating hippocampal norepinephrine release. I. Location on axon terminals and pharmacological characterization.
    Pittaluga A; Raiteri M
    J Pharmacol Exp Ther; 1992 Jan; 260(1):232-7. PubMed ID: 1370540
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Properties of amino acid neurotransmitter receptors of embryonic cortical neurons when activated by exogenous and endogenous agonists.
    Blanton MG; Kriegstein AR
    J Neurophysiol; 1992 May; 67(5):1185-200. PubMed ID: 1350794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease.
    Hynd MR; Scott HL; Dodd PR
    Neurochem Int; 2004 Oct; 45(5):583-95. PubMed ID: 15234100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The interplay of neurotransmitters in Alzheimer's disease.
    Francis PT
    CNS Spectr; 2005 Nov; 10(11 Suppl 18):6-9. PubMed ID: 16273023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deficient NMDA-mediated glutamate release from synaptosomes of schizophrenics.
    Sherman AD; Hegwood TS; Baruah S; Waziri R
    Biol Psychiatry; 1991 Dec; 30(12):1191-8. PubMed ID: 1686412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Density and distribution of NMDA receptors in the human hippocampus in Alzheimer's disease.
    Geddes JW; Chang-Chui H; Cooper SM; Lott IT; Cotman CW
    Brain Res; 1986 Dec; 399(1):156-61. PubMed ID: 2879613
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of β-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices.
    Rammes G; Hasenjäger A; Sroka-Saidi K; Deussing JM; Parsons CG
    Neuropharmacology; 2011 May; 60(6):982-90. PubMed ID: 21310164
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brainstem excitatory amino acid receptors in nociception: microinjection mapping and pharmacological characterization of glutamate-sensitive sites in the brainstem associated with algogenic behavior.
    Jensen TS; Yaksh TL
    Neuroscience; 1992; 46(3):535-47. PubMed ID: 1347650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of AMPA receptor function in relation to glutamatergic abnormalities in Alzheimer's disease.
    Madsen U; Ebert B; Krogsgaard-Larsen P
    Biomed Pharmacother; 1994; 48(7):305-11. PubMed ID: 7858161
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rodent models of memory dysfunction in Alzheimer's disease and normal aging: moving beyond the cholinergic hypothesis.
    Ingram DK; Spangler EL; Iijima S; Ikari H; Kuo H; Greig NH; London ED
    Life Sci; 1994; 55(25-26):2037-49. PubMed ID: 7997063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of neuronal energy in the neurotoxicity of excitatory amino acids.
    Henneberry RC
    Neurobiol Aging; 1989; 10(5):611-3; discussion 618-20. PubMed ID: 2572985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.